Metzger; Edward

Patent Applications and Registrations

Patent applications and USPTO patent grants for Metzger; Edward.The latest application filed is for "substituted aminoquinazoline compounds as a2a antagonist".

Company Profile

1.15.18

Metzger; Edward - Laurel MD
Metzger; Edward - Somerset NJ
Metzger; Edward - Beltsville MD
METZGER; Edward - Rahway NJ US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
2,2-difluorodioxolo A.sub.2A receptor antagonists Grant 11,046,714 - Amjad , et al. June 29, 2	2021-06-29
Substituted aminoquinazoline compounds as A.sub.2A antagonist Grant 10,822,338 - Ali , et al. November 3, 2	2020-11-03
Substituted Aminoquinazoline Compounds As A2a Antagonist App 20180362530 - Ali; Amjad ; et al.	2018-12-20
Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties Grant 10,011,615 - Ali , et al. July 3, 2	2018-07-03
Indoline compounds as aldosterone synthase inhibitors Grant 9,745,282 - Ali , et al. August 29, 2	2017-08-29
Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine Compounds With A2a Antagonist Properties App 20170197991 - Ali; Amjad ; et al.	2017-07-13
Indoline compounds as aldosterone synthase inhibitors Grant 9,550,750 - Ali , et al. January 24, 2	2017-01-24
Indoline Compounds As Aldosterone Synthase Inhibitors App 20160304486 - Ali; Amjad ; et al.	2016-10-20
2,2-difluorodioxolo A2a Receptor Antagonists App 20160214997 - Amjad; Ali ; et al.	2016-07-28
Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine Compounds With A2a Antagonist Properties App 20150361098 - Ali; Amjad ; et al.	2015-12-17
Diazeniumdiolate heterocyclic derivatives Grant 9,108,920 - Ali , et al. August 18, 2	2015-08-18
Indoline Compounds As Aldosterone Synthase Inhibitors App 20150225365 - Ali; Amjad ; et al.	2015-08-13
Diazeniumdiolate cyclopentyl derivatives Grant 8,648,058 - Ali , et al. February 11, 2	2014-02-11
Diazeniumdiolate Derivatives App 20130296278 - Ali; Amjad ; et al.	2013-11-07
Diazeniumdiolate Heterocyclic Derivatives App 20130289003 - Ali; Amjad ; et al.	2013-10-31
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use Grant 8,436,015 - Lin , et al. May 7, 2	2013-05-07
Diazeniumdiolate Cyclopentyl Derivatives App 20130053352 - Ali; Amjad ; et al.	2013-02-28
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use Grant 8,324,384 - Lin , et al. December 4, 2	2012-12-04
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use Grant 8,318,667 - Lin , et al. November 27, 2	2012-11-27
Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use App 20110306624 - Lin; Songnian ; et al.	2011-12-15
Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use App 20110301082 - Lin; Songnian ; et al.	2011-12-08
Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use App 20110172256 - Lin; Songnian ; et al.	2011-07-14

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.